Business
Correction of a Material Error Relating to the Total Number of Voting Rights and Shares Comprising the Share Capital
Correction of a Material Error Relating to the Total Number of Voting Rights and Shares Comprising the Share CapitalClarification in Response to Unfounded Accusations NANTES, France – September 24, 2025, 8:00 a.m. CET – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) corrects the information relating to the total number of shares and voting rights comprising its share capital. As part of the preparation for the General Meeting on September 30, 2025, OSE identified a processing error r
About this update from Ose Immunotherapeutics Sa
[{"type":"image","alt":"OSE Immunotherapeutics","displaySize":"","headline":null,"caption":"OSE Immunotherapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":100,"url":"https://media.zenfs.com/en/globenewswire.com/bca4e9e3611afcc1a4e99230a01fa8eb"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/h55Oot7mWh39J7Yvj1GueA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0MDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/bca4e9e3611afcc1a4e99230a01fa8eb","width":300,"height":100}},"lazy":false},{"type":"text","content":"Correction of a Material Error Relating to the Total Number of Voting Rights and Shares Comprising the Share CapitalClarification in Response to Unfounded Accusations","length":168,"tagName":"p"},{"type":"text","content":"","length":0,"tagName":"p"},{"type":"text","content":"NANTES, France – September 24, 2025, 8:00 a.m. CET – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) corrects the information relating to the total number of shares and voting rights comprising its share capital. As part of the preparation for the General Meeting on September 30, 2025, OSE identified a processing error related to the acceleration - recorded between June and September 2025 by the Board of Directors - of the vesting period for 546,919 free shares.","length":479,"tagName":"p"},{"type":"text","content":"This material error, which has no impact on the rights of the beneficiaries nor on votes already cast, was acknowledged and immediately corrected by the Board of Directors at its meeting on September 23. All necessary measures have been taken to inform the shareholders concerned.","length":280,"tagName":"p"},{"type":"text","content":"The number of outstanding shares comprising the share capital is 22,463,262. The number of theoretical1 voting rights is 27,859,524.","length":132,"tagName":"p"},{"type":"text","content":"Clarification in Response to Unfounded Accusations","length":50,"tagName":"p"},{"type":"text","content":"OSE firmly refutes the unfounded and false allegations disseminated by the group of concerted minority shareholders, accusing the Executive Management and the Board of Directors of “fraudulent manipulation.” The identified processing error does not in any way result from a deliberate act, let alone a fraudulent one. It stems from an inaccurate legal qualification by one of the Company’s corpor...